Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NGM Biopharmaceuticals, Inc. NGM NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$16.50
+971.4%

NGM Biopharmaceuticals, Inc. (NGM) is a Biotechnology company in the Healthcare sector, currently trading at $1.54. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is NGM = $17 (+971.4% upside).

Financials: revenue is $4M, -43.9%/yr average growth. Net income is $142M (loss), growing at -16.8%/yr. Net profit margin is -3223.3% (negative). Gross margin is 49.7% (+137.4 pp trend).

Balance sheet: total debt is $0 against $149M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 7.79 (strong liquidity). Debt-to-assets is 0%. Total assets: $169M.

Analyst outlook: 10 / 15 analysts rate NGM as buy (67%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 43/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).

$16.50
▲ 971.43% Upside
Average Price Target
Based on 15 Wall Street analysts offering 12-month price targets for NGM Biopharmaceuticals, Inc., the average price target is $16.50, with a high forecast of $29.00, and a low forecast of $4.00.
Highest Price Target
$29.00
Average Price Target
$16.50
Lowest Price Target
$4.00

NGM SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 43/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NGM

✓
VALUE Pass
100/100
NGM trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $17, implying +1003.9% from the current price $2. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
NGM: -43.9%/yr revenue is, -16.8%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NGM: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 7.79 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
43/100
NGM: Gross margin is 49.7% (+137.4 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 43/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 10 / 15 analysts rate NGM as buy (67%). Analyst consensus target is $17 (+1003.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
NGM: Net profit margin is -3223.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.6002-4.69
Volume2.21M
Avg Volume (30D)1.07M
Market Cap$128.53M
Beta (1Y)1.26
Share Statistics
EPS (TTM)-1.73
Shares Outstanding$82.5M
IPO Date2019-04-04
Employees138
CEODavid J. Woodhouse
Financial Highlights & Ratios
Revenue (TTM)$4.42M
Gross Profit$2.2M
EBITDA$-144.33M
Net Income$-142.38M
Operating Income$-146.55M
Total Cash$147.18M
Net Debt$-58.82M
Total Assets$168.87M
Price / Earnings (P/E)-0.9
Price / Sales (P/S)29.1
Analyst Forecast
1Y Price Target$16.50
Target High$29.00
Target Low$4.00
Upside+971.4%
Rating ConsensusBuy
Analysts Covering15
Buy 67% Hold 33% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS62921N1054

Price Chart

Track all markets on TradingView
NGM
NGM Biopharmaceuticals, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
0.60 52WK RANGE 4.69

People Also View

ERAS
ERAS
Erasca, Inc.
$18.20
+1.96%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$30.42
+11.35%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$18.23
+4.17%
 SANA
SANA
Sana Biotechnology, Inc.
$3.44
-1.15%
 LYEL
LYEL
Lyell Immunopharma, Inc.
$23.84
+2.01%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.81
+1.26%
 KROS
KROS
Keros Therapeutics, Inc.
$11.71
+1.39%
 RZLT
RZLT
Rezolute, Inc.
$3.59
+1.13%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message